Menu
Menu
Listen to what Prof. Sarin has to say about how hereditary cancer testing has evolved at Tata Memorial Hospital and the importance of detecting CNVs and variants in complex genes like PMS2.
Learn why one of Austria's largest tertiary care hospitals chose to consolidate its fragmented molecular workflows into a single, comprehensive solution covering biomarkers across both myeloid and lymphoid malignancies, and the impact the team expects it to have on their day-to-day routine.
In this interview, TomaLab's team shares why their lab adopted an integrated workflow with SOPHiA DDM™ and Element AVITI™ across multiple applications, and what's changed for them since.
In this spotlight, Beatriz Hidalgo from Hereditary Cancer Unit at Hospital Universitario 12 de Octubre shares insights from a decade of collaboration with SOPHiA GENETICS and how robust, standardized workflows are helping her team navigate growing testing volumes and increasingly complex genomic data in hereditary cancer.
Pharmacogenetics is moving from a specialized testing approach toward an increasingly integrated part of precision medicine. In this User Spotlight, Prof. Nicolas Picard, Head of the French-speaking network of Pharmacogenetics (RNPGx) at Limoges University Hospital, France, discusses the evolution of pharmacogenomics in clinical practice, the importance of collaboration between clinical experts and technology innovators, and […]
In this short interview, Arantxa Hervás, CGT Dx Director at Vitrolife Group, shares why her lab moved from a multi-test NGS model to the SOPHiA DDM™ Enhanced Clinical Exome Solution, and what has changed for them since.
For Gorka Alkorta-Aranburu, Head of the Genetics and Genomics Diagnostic Laboratory at Clínica Universidad de Navarra, the move to whole genome sequencing (WGS) was a deliberate leap, not a gradual one.
Read our latest user spotlight, featuring Dr. Hemad Yasaei, Head of Molecular Genomics at the National Reference Laboratory (M42) in Abu Dhabi.
Explore how Dasa and SOPHiA GENETICS are collaborating to advance precision oncology research and drive real-world impact.
In this user spotlight, we had the pleasure of interviewing Dr. Robert Akkers, Molecular Biologist at Result Laboratorium, one of our valued and long-standing partners in the Netherlands.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.